Humana Inc 8-K Filing

FAQ

Key Financial Figures

• $12.26 — reaffirms its guidance of approximately $12.26 in diluted earnings per common share ("
• $17.00 — r common share ("EPS") or approximately $17.00 in adjusted earnings per common share (

Filing Documents

• hum-20251216.htm (8-K) — 44KB
• exhibit991newsrelease.htm (EX-99.1) — 11KB
• humanalogoa.jpg (GRAPHIC) — 14KB
• 0000049071-25-000061.txt ( ) — 194KB
• hum-20251216.xsd (EX-101.SCH) — 2KB
• hum-20251216_lab.xml (EX-101.LAB) — 21KB
• hum-20251216_pre.xml (EX-101.PRE) — 12KB
• hum-20251216_htm.xml (XML) — 3KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. The Company reaffirms its guidance of approximately $12.26 in diluted earnings per common share ("EPS") or approximately $17.00 in adjusted earnings per common share ("Adjusted EPS"), in each case for the year ending December 31, 2025 ("FY 2025"). This guidance is consistent with the guidance issued in the Company's press release dated November 5, 2025 and Form 8-K filed on December 1, 2025. The Company has included Adjusted EPS in this current report, a financial measure that is not in accordance with Generally Accepted Accounting Principles ("GAAP"). Management believes that this measure, when presented in conjunction with the comparable measure of GAAP EPS, provides a comprehensive perspective to more accurately compare and analyze the Company's core operating performance over time. Consequently, management uses Adjusted EPS as a consistent and uniform indicator of the Company's core business operations from period to period, as well as for planning and decision-making purposes and in determination of incentive compensation. Adjusted EPS should be considered in addition to, but not as a substitute for, or superior to, GAAP EPS. A reconciliation of GAAP EPS to Adjusted EPS follows: Diluted earnings per common share FY 2025 Guidance GAAP approximately $12.26 Amortization of identifiable intangibles 0.42 Put/call valuation adjustments associated with the Company's non-consolidating minority interest investments (a) 3.81 Value creation initiatives (a) 2.65 Impact of exit of employer group commercial products business (a) (0.52) Settlement of certain litigation expenses (a) 0.13 Loss on sale of business (a) 0.52 Impairment charges (a) 0.27 Cumulative net tax impact (2.54) Adjusted (non-GAAP) – FY 2025 projected (a) approximately $17.00 (a) FY 2025 GAAP EPS guidance and FY 2025 Adjusted (non-GAAP) EPS guidance exclude the impact of future value changes to items that have not yet been recognized or cannot be reason

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibit s: Exhibit No. Description 99.1 Press Release 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. HUMANA INC. BY: /s/ Joseph C. Ventura Joseph C. Ventura Chief Legal Officer Dated: December 16, 2025

View Full Filing

View this 8-K filing on SEC EDGAR